Pasithea Therapeutics Corp. (KTTAW)

The security is trading at a price of $0.0097, which is identical to its 52-week low, indicating severe distress and a lack of recent upward momentum. Fundamentally, the company is burning cash aggressively with operating cash flow of -$16.9 million and free cash flow of -$11.8 million, while posting significant losses on both assets (-31.5%) and equity (-58.2%). Despite holding substantial cash reserves of roughly $50 million, the massive burn rate suggests these funds will deplete quickly without a proven path to profitability or a successful clinical trial outcome. There is no dividend history, and the absence of annual price anchors implies the stock may be newly listed or has suffered a complete delisting/zeroing out event, rendering any long-term historical performance analysis impossible. The statistical forecasting model predicts a 22% gain but flags its reliability as 'VERY LOW' due to extreme data anomalies, making this prediction useless for decision-making. Given the deteriorating fundamentals, massive cash bleed, and lack of price history, the investment case is currently non-existent.